TYROSINE KINASE INHIBITORS AND INTERFERON

Maria Dimou, Panagiotis Panagiotidis
  • Maria Dimou
    1st Department of Propaedutic Medicine, Division of Hematology, University of Athens, Greece, Greece
  • Panagiotis Panagiotidis
    1st Department of Propaedutic Medicine, Division of Hematology, University of Athens, Greece, | ppanayi@med.uoa.gr

Abstract

The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfit for bone marrow transplantation. With the appearance of the first Tyrosine Kinase Inhibitor (TKI) (imatinib) and based on the results of the pivotal IRIS trial, imatinib monotherapy was the new treatment of choice for CML, according to the ELN recommendations. The possibility of combining INF with imatinib, for obtaining better therapeutic responses in CML patients has been already tested and reported. The current challenge is the combined use of second generation TKIs with pegylated –IFN, in order to minimize failures to therapy and increase the number of CML patients with deep molecular responses, who may be able to discontinue lifelong treatment.

Keywords

tyrosine kinase inhibitors; interferon-alpha; chronic myeloid leukemia; pegylated interferon alpha; treatment discontinuation

Full Text:

PDF
HTML
Submitted: 2014-07-21 14:04:48
Published: 2014-01-02 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
410

Views:
PDF
216
HTML
1111

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Comments on this article

View all comments


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185